Highest International Standard
In Europe, we have two production sites - one in Pfaffenhofen (Germany) and another one in Altkirch (France). Both are regularly visited by national and international authorities such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA). State-of-the-art facilities and automation ensure a consistently high production quality.
Especially Pfaffenhofen contributes significantly to our global production capacity. Pharmaceuticals are not only manufactured, but also developed here. This includes the entire Olmesartan product range but also Edoxaban which from here are exported as bulk or finished packs into more than 50 countries on four continents. More than 80 million blister and about two billion tablets are produced each year. Pfaffenhofen's activities comprise biotechnology api (active pharmaceutial ingredients) manufacturing and the production of solid pharmaceutical products (tablets and film-coated tablets).
In our production facility in Altkirch, France, we manufacture active pharmaceutical ingredients for our traditional Luitpold products.
Pfaffenhofen also plays a key role in pharmaceutical development and globally assumes a leading role for an increasingly large number of galenic research projects. The goal of pharmaceutical development is to produce applicable medicines, such as tablets, from active ingredients. Our German team for example investigates how active ingredients are metabolised, defines the optimal formulation for the related medicine, examines the best production methods for the drug and evaluates the stability of the new drug formulation. This time-consuming and diligent approach is a vital prerequisite to making high-quality and safe pharmaceutical products available to patients worldwide.